GSK plc (LON:GSK)

Market Cap	78.06B +41.1%
Revenue (ttm)	32.67B +4.1%
Net Income	5.72B +122.0%
EPS	1.39 +123.2%
Shares Out	4.01B
PE Ratio	14.02
Forward PE	10.56
Dividend	0.61 (3.14%)
Ex-Dividend Date	Nov 13, 2025

Volume	16,789,740
Average Volume	7,126,710
Open	1,935.50
Previous Close	1,945.50
Day's Range	1,920.00 - 2,111.50
52-Week Range	1,242.50 - 2,111.50
Beta	0.27
RSI	77.16
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1715
• Employees: 68,629
• Stock Exchange: London Stock Exchange
• Ticker Symbol: GSK

Financial Performance

In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.